Obesity Featured Articles

  1. Bridging The Patient Journey With Real-World Outcomes Using Tokenization 6/27/2025

    Explore the growing role of real-world data (RWD) and tokenization in enhancing clinical research and patient-centered evidence generation.

  2. Gilead Art Campaign Captures The PBC Patient Experience, Inspires Patient-Centric Trials 6/27/2025

    Gilead’s Carrie Frenette discusses the company's art campaign centered on primary biliary cholangitis to bring awareness to the condition and create more patient-centric trials for patients.

  3. Population-Aware Medicine: Mitigating Racial Disparities In Efficacy And Accuracy 6/26/2025

    Medicine is not one-size-fits-all. Here, strategic advisor Bill Hanlon implores pharma to develop therapeutics and diagnostics anchored by racial and ethnic diversity.

  4. Top Technologies Transforming Decentralized Clinical Trials 6/26/2025

    In today’s clinical development environment, DCT technologies are not optional innovations; they are essential drivers of more resilient, efficient, and patient-focused trials.

  5. Data-Driven Decision-Making In Clinical Trials 6/25/2025

    By leveraging real-time data and predictive tools, sponsors and CRO's can address the increasing complexity of trials, accelerate therapeutic development, and proactively manage risks.

  6. It's Time To Change How We Engage Research Sites 6/25/2025

    Site operations expert Maria Ladd argues for a major change in how sponsors and CROs communicate and work with clinical research sites.

  7. A Deep Dive Into Clinical Trial Payment Types, Methods, And Amounts 6/24/2025

    Explore key themes surrounding payments to clinical research participants in depth, with a particular focus on the role of participant compensation and best practices in payment logistics.

  8. The Effects Of Most Favored Nation Drug Pricing On Clinical Trial Management 6/24/2025

    Market expert Mathini Ilancheran explains how sponsors can mitigate the effects of "Most Favored Nation" drug pricing while maintaining trial integrity and accelerating time to market.

  9. Navigating FDA Regulatory Changes: Policy Shifts, Deregulation, Restructuring, And Future Oversight 6/23/2025

    Recent shifts within the U.S. FDA reflect an increasingly complex tension between scientific rigor and accelerating political and economic pressures. Here are the newest developments and emerging focal points.

  10. Understanding FDA's Draft Guidance: Composition Statements Of Ingredients In Labeling In NDAs And ANDAs 6/20/2025

    The FDA's 2024 draft guidance details presentation of a drug product’s composition and the corresponding details of the ingredients in the product labels for NDAs and ANDAs.